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for patients with ≥6 months of follow-up (N = 73). The NNT to prevent one 
death, one event (death or use of permanent assisted ventilation), or for one 
patient to improve motor function relative to nusinersen was calculated as the 
reciprocal of the difference between AVXS-101 and nusinersen in event rates 
or motor function achievement rates. Patient mean age at first dose was 3.4 
(0.9-7.9) and 5.3 (1.7-7.9) months in the AVXS-101 and nusinersen trials. 
NNT analyses suggests that treating 6.2 patients with AVXS-101 instead of 
nusinersen would prevent 1 more death by the last visit; treating 2.6 patients 
with AVXS-101 versus nusinersen would prevent 1 more event; and treating 
3.5 patients with AVXS-101 versus nusinersen would allow 1 more patient 
to improve motor function (at last visit and at a median of 9 months). Ef- 
ficacy in preventing death and use of permanent assisted ventilation and in 
improving motor function is much higher with AVXS-101 versus nusinersen. 
http://dx.doi.org/10.1016/j.nmd.2018.06.124 
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Economic considerations are increasingly important to help decision mak- 
ers to efficiently allocate health care resources. To date, very little information 
is available on the cost-effectiveness of spinal muscular atrophy (SMA) treat- 
ment and newborn screening; yet more and more screening programs are be- 
ing implemented in the USA and in Europe. The aim of this study is therefore 
to develop a decision-analytic model to assess the cost-effectiveness of new- 
born screening and pre-symptomatic treatment of SMA as compared to post- 
symptomatic treatment. Newborn screening for SMA has started since Marsh 
05th in Southern Belgium. We are developing a decision-analytic model in 
Excel with a lifetime horizon and a societal perspective. This model includes 
events (such as death, permanent ventilation, etc), transition, utilities, and 
costs. Data was retrieved from literature reviews, available non-published 
data from Nurture, and data collected from the European Natural History 
Study in SMA. We also collected data from the large post symptomatic 
treated cohort of Liege, Belgium. All such data was acquired in centers ap- 
plying updated standards of care. The quality of life of patients and parents 
was included in the analysis, as well as the productivity losses of parents. 
The model thus estimates the costs and effects (expressed in quality-adjusted 
life years) of newborn screening and to compare it with a situation where all 
patients are diagnosed post-symptomatically. Initial data suggests promising 
results and reveal key factors on the cost-effectiveness of NBS. The model 
requires adjustment to be fully validated. 
http://dx.doi.org/10.1016/j.nmd.2018.06.125 
LGMD AUTOSOMAL RESSESSIVE AND DOMINANT 
P.98 
AAV-mediated gene transfer of FKRP for therapy of LGMD2I 
E. Gicquel 1 , S.C. Brown 2 , I. Richard 1 
1 Genethon, Evry, France; 2 Royal Veterinary College, London, UK 
Dystroglycanopathies constitute a group of genetic diseases caused by 
defective glycosylation of alpha-dystroglycan α, a membrane glycoprotein 
involved in the cell/matrix anchoring of muscle fibers. The aDG glycosyla- 
tion, a very complex process, requires many proteins whose functions are not 
fully elucidated. In particular, mutations in the FKRP gene encoding Fukutin 
related protein lead to hypoglycosylation of α, resulting in different forms 
of dystroglycanopathies, among which Limb Girdle Muscular Dystrophy 
type 2I (LGMD2I). We and others have published the proof of concept of 
FKRP gene transfer using an AAV vector for treating FKRP deficiencies. 
As the knock-in mouse models used in these studies are not severe enough 
to evaluate properly the dose-effect of AAV-FKRP administration, we devel- 
oped a muscle specific FKRP knock-down mouse model. This new mouse 
model, named HSA-FKRPdel, presents a much more severe phenotype than 
observed in knock-in mouse. Defects of glycosylation of αDG and of its 
binding to laminin were observed, as well as histological dystrophic signs as 
centronucleation and inflammation. Functional evaluation also showed 
a reduced force of HSA-FKRPdel mice. AAV- FKRP was systemically 
administrated to this new mouse model at different doses. Depending of 
the dose, positive effects were observed at the molecular, histological and 
functional levels. Full animal characterization and therapeutic effects will 
be presented. Development of AAV production at the GMP level is now on 
going. These data will be included in an IND for AAV-mediated transfer of 
FKRP in patients. 
http://dx.doi.org/10.1016/j.nmd.2018.06.126 
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Mutations in POGLUT1 (protein O-glucosyltransferase 1), an enzyme 
involved in Notch posttranslational modification and function have been re- 
cently identified as causing a new type of limb-girdle muscular dystrophy, 
known as LGMD2Z. The clinical features of the identified patients encom- 
passed variable clinical onset from 1st to 5th decade, muscle weakness pre- 
dominantly in the proximal lower limbs, followed by upper limb involve- 
ment and wheelchair confinement. We report a Bulgarian family with three 
affected sisters, homozygous for R98W mutation in POGLUT1 . They un- 
derwent neurological examination, electromyography, measurement of cre- 
atine kinase, ventilatory assessment, electrocardiography, echocardiography 
and muscle muscle magnetic resonance imaging (MRI). The initial com- 
plaints in two of them were noticed at the age of 24-25 years, while in the 
third- at the age of 44 years. The leading symptoms at onset were muscle 
weakness in the proximal leg muscles with difficulties in climbing stairs and 
getting up from squatting position. The involvement of the upper limbs was 
noticed between 6 and 23 years after the lower limb weakness. CK was within 
normal range in all three affected. The cardiac function seamed spared, mild 
restrictive respiratory involvement was observed in only one of the sisters. 
MRI of the legs revealed early fatty replacement of internal regions of thigh 
muscles and sparing of the external areas. In conclusion POGLUT1 muta- 
tions are associated with late onset AR LGMD with specific MRI pattern of 
inside-to-outside mode of fatty degeneration in the lower limbs. 
http://dx.doi.org/10.1016/j.nmd.2018.06.127 
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BVES encodes for a 360 amino acid protein also known as POPDC1, 
which is part of the Popeye domain containing (POPDC) family of pro- 
teins. POPDC1, POPDC2 and POPDC3 are cAMP-binding transmembrane 
proteins that are abundantly expressed in striated muscle. A homozygous 
